Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: The objective of this study was to compare the accumulated clinical outcomes of two Malaysian all-comers populations, each treated with different polymer-free sirolimus-eluting stents (PF-SES) of similar stent design.
Methods: The Malaysian subpopulation of two all-comers observational studies based on the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were combined and compared to a Malaysian-only cohort which was treated with a later-generation PF-SES. The PF-SES's used differed only in their bare-metal backbone architecture, with otherwise identical sirolimus coating. The primary endpoint was the accumulated target lesion revascularization (TLR) rate at 12 months. The rates of major adverse cardiac events (MACE), stent thrombosis (ST) and myocardial infarction (MI) were part of the secondary endpoints.
Results: A total of 643 patients were treated with either the first-generation PF-SES (413 patients) or second-generation PF-SES (230 patients). Patient demographics were similar in terms of age (p = 0.744), male gender (0.987), diabetes mellitus (p = 0.293), hypertension (p = 0.905) and acute coronary syndrome (ACS, 44.8% vs. 46.1%, p = 0.752) between groups. There were no differences between treatment groups in terms of lesion length (20.8 ± 7.3 mm vs. 22.9 ± 7.9, p = 0.111) or vessel diameter (2.87 ± 0.39 vs. 2.93 ± 0.40, p = 0.052) despite numerically smaller diameters in the first-generation PF-SES group. The second-generation PF-SES tended to have more complex lesions as characterized by calcification (10.3% vs. 16.2%, p = 0.022), severe tortuosity (3.5% vs. 6.9%, p = 0.041) and B2/C lesions (49.2% vs. 62.8%, p < 0.001). The accumulated TLR rates did not differ significantly between the first- and second-generation PF-SES (0.8% vs. 0.9%, p = 0.891). The accumulated MACE rates were not significantly different (p = 0.561), at 1.5% (6/413) and 2.2% (5/230), respectively.
Conclusions: Modifications in coronary stent architecture which enhance the radial strength and radiopacity without gross changes in strut thickness and design do not seem to impact clinical outcomes.
Clinical Trial Registration: ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126533 | PMC |
| http://dx.doi.org/10.1007/s40119-020-00204-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Science progress distinguishing different types of airway stents under bronchoscopy by artificial intelligence.
Sci Prog
August 2025
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
ObjectiveIn prior research, we employed artificial intelligence (AI) to distinguish different anatomical positions in the airway under bronchoscopy. We aimed to leverage AI to identifying different types of airway stent.MethodsTo "deep learn" imaging data from patients who underwent bronchoscopy for implanting airway stents from January 2010 to June 2024, utilizing the Vision Transformer model (AI architecture).
View Article and Find Full Text PDFNIR-Plasmon Enhanced MXene/Fe-MOFs Composite Scaffold for Synergistic Chemodynamic-Photothermal Antibacterial Therapy in Bone Implants.
ACS Appl Bio Mater
August 2025
Jiangxi Provincial Key Laboratory of Additive Manufacturing of Implantable Medical Device, Jiangxi University of Science and Technology, Nanchang 330013, China.
Bacterial infection remains a critical challenge in bone stent implantation, often leading to implantation failure. This study proposes a synergistic antibacterial strategy combining photothermal therapy and plasmon-enhanced CDT within a 3D-printed bioactive scaffold. Porous polylactic acid bone scaffolds incorporated with TiC-MXene/Fe-MOFs nanocomposites were fabricated using selective laser sintering technology.
View Article and Find Full Text PDF3D printing of stents via two-photon polymerization.
Sci Rep
July 2025
Vital3D Technologies, Saulėtekio Ave. 15, 10224, Vilnius, Lithuania.
Stents are medical devices used to treat the narrowing of the blood vessel, most commonly caused by atherosclerosis. Currently used bare-metal, drug-eluting stents are limited in size and architectural complexity, and there are a few risks associated with these medical devices. In some cases stents can cause thrombosis or even death.
View Article and Find Full Text PDFThe impact of stenosis treatment on the hemodynamic crosstalk between carotid arteries.
Sci Rep
July 2025
Operative Unit of Vascular Surgery, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Biomechanical analysis of crosstalk between the carotids remains poorly underexplored. This study aims to clarify the impact of severe carotid stenosis on the local hemodynamics of the opposite carotid artery, before and after treatment. Data from patients diagnosed with severe internal carotid artery stenosis (≥ 70%), treated with carotid artery stenting (CAS) or carotid endarterectomy (CEA) were analyzed.
View Article and Find Full Text PDFElectrochemical Assessment of the Galvanic Corrosion and Metal Ion Release in Overlapping Stent and Vascular Plug Systems.
J Biomed Mater Res A
June 2025
Department of Biomedical Engineering, Faculty of Engineering, Cukurova University, Adana, Türkiye.
Cardiovascular diseases cause the highest global mortality rates and are often treated with surgical interventions such as stent or vascular plug placement. However, in-stent restenosis develops over time depending on the material composition and interactions with body fluids. Current strategies to address restenosis include balloon angioplasty or placing a secondary stent at the same site.
View Article and Find Full Text PDF